ClinicalTrials.gg

Program

tulisokibart

Also written as “Tulisokibart”, “IV Tulisokibart” and “SC Tulisokibart”.

Its studies are mostly in Crohn Disease · Colitis, Ulcerative · Panuveitis · Sarcoidosis, Pulmonary · Axial Spondyloarthritis, led by Merck.

Furthest: phase 3, since Sep 18, 202317 company-led studies, 10 open or runningNext primary completion: Feb 17, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck1710 open or runningphase 3since Sep 18, 2023Dec 9, 2020Feb 17, 2027phase 2 · NCT07486960
  • Named in Merck’s own pipeline as tulisokibart (MK-7240), phase 3, as of Nov 2, 2026 (source).

Also a collaborator on its studies: ppd-part-of-thermo-fisher-scientific, celerion and altasciences-company-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Dec 9, 2020.

  1. Feb 27, 2022Phase 2 study in Scleroderma, DiffuseNCT05270668 · 154 enrolled · United States, Argentina, Australia and more
  2. Apr 1, 2022Phase 1 study in HealthyNCT05354349 · 49 enrolled · United States
  3. Sep 18, 2023Phase 3 study in Colitis, UlcerativeNCT06052059 · 1,109 enrolled · United States, Argentina, Australia and more
  4. May 21, 2024Phase 3 study in Crohn DiseaseNCT06430801 · 1,200 planned · United States, Australia, Austria and more
  5. Aug 16, 2024Phase 1 study in HealthyNCT06575595 · 60 enrolled · United States
  6. Oct 18, 2024Phase 3 study in Crohn DiseaseNCT06651281 · 1,380 planned · United States, Czechia, France and more
  7. Feb 11, 2025Phase 1 study in Colitis, UlcerativeNCT06829225 · 48 enrolled · China
  8. Apr 30, 2025Phase 2 study in Hidradenitis SuppurativaNCT06956235 · 149 enrolled · United States, Argentina, Australia and more
  9. Aug 14, 2025Phase 2 study in Radiographic Axial SpondyloarthritisNCT07133633 · 315 enrolled · United States, Brazil, Canada and more
  10. Sep 9, 2025Phase 2 study in Arthritis, RheumatoidNCT07176390 · 185 enrolled · United States, Canada, Chile and more
  11. Feb 5, 2026Phase 1 study in HealthyNCT07405177 · 330 enrolled · Australia
  12. Mar 19, 2026Phase 2 study in Arthritis, PsoriaticNCT07486960 · 140 enrolled · United States, Canada, Chile and more
  13. Sep 30, 2026Phase 2 study in PanuveitisNCT07861074 · 87 planned · United States, Canada
  14. Oct 5, 2026Phase 2 study in Sarcoidosis, PulmonaryNCT07867938 · 158 planned · United States

Ahead

  1. Feb 17, 2027Primary completion: phase 2 study in Arthritis, PsoriaticNCT07486960
  2. Mar 29, 2027Primary completion: phase 2 study in Radiographic Axial SpondyloarthritisNCT07133633
  3. Oct 30, 2028Primary completion: phase 3 study in Crohn DiseaseNCT06430801
  4. Jun 5, 2029Primary completion: phase 2 study in PanuveitisNCT07861074

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07867938Sarcoidosis, Pulmonary · United States2RecruitingOct 5, 2029158
NCT07861074Panuveitis · United States, Canada2RecruitingJun 5, 202987
NCT07486960Arthritis, Psoriatic · United States, Canada, Chile and more2Active, not recruitingFeb 17, 2027140
NCT07405177Healthy · Australia1CompletedSep 19, 2026330
NCT07176390Arthritis, Rheumatoid · United States, Canada, Chile and more2Active, not recruitingSep 7, 2026185
NCT07133633Radiographic Axial Spondyloarthritis · United States, Brazil, Canada and more2Active, not recruitingMar 29, 2027315
NCT06956235Hidradenitis Suppurativa · United States, Argentina, Australia and more2Active, not recruitingApr 2, 2026149
NCT06829225Colitis, Ulcerative · China1CompletedNov 11, 202448
NCT06651281Crohn Disease · United States, Czechia, France and more3RecruitingDec 17, 20371,380
NCT06575595Healthy · United States1CompletedJan 31, 202560
NCT06430801Crohn Disease · United States, Australia, Austria and more3RecruitingOct 30, 20281,200
NCT06052059Colitis, Ulcerative · United States, Argentina, Australia and more3Active, not recruitingAug 12, 20261,109
NCT05354349Healthy · United States1CompletedAug 31, 202249
NCT05270668Scleroderma, Diffuse · United States, Argentina, Australia and more2Active, not recruitingApr 16, 2026154
NCT05013905Crohn Disease · United States, Australia, Belgium and more2CompletedSep 23, 202255
NCT04996797Colitis, Ulcerative · United States, Australia, Belgium and more2CompletedJun 6, 2023178
NCT04676178Healthy · United States1CompletedSep 23, 202169

How it is read

Names in the registry

  • “Tulisokibart”, 12 entries
  • “IV Tulisokibart”, 2 entries
  • “SC Tulisokibart”, 2 entries
  • “Tulisokibart Form 1”, 1 entry
  • “Tulisokibart Form 2”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.